News
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
Sarepta (NASDAQ:SRPT) stock, Replimune (NASDAQ:REPL) stock and Capricor (CAPR) stock surge as FDA's biologics head exits abruptly. Read more here.
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Zacks Investment Research on MSN2d
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Wall Street expects a year-over-year increase in earnings on higher revenues when Sarepta Therapeutics (SRPT) reports results ...
Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback